Clinical Laboratory
....FOR INFORMED DECISIONS
Epic Sciences mission is to improve patient lives by enabling precision medicine and personalize treatments.
To accomplish our mission, we are using our proprietary circulating tumor cell (CTC) detection platform to develop predictive tests of therapy benefit. These tests will provide essential information to physicians, helping them guide treatment decisions to extend patient lives. These tests are being developed in our Clinical Laboratory (CLIA ID: 05D2087488).
Clinical Laboratory Tests
Characterization of nuclear AR-V7+ CTCs as a biomarker for informed mCRPC treatment decisions
learn more at www.arv7.com
Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test
to Predict Treatment Response in Metastatic Prostate Cancer
UP TO DATE WITH EPIC SCIENCES
JUST RELEASED: Study from MSK and Epic Sciences shows only nuclear-localized AR-V7 is predictive of therapy benefit for patients with metastatic prostate cancer.